Payment overview · 2025
General Payments
$707.38
36 reported records · 15 companies
Healthcare provider profile · identity verified
Shery Thomas, MD
Allopathic & Osteopathic Physicians|Internal Medicine · E LIVERPOOL, OH · NPI 1467478388
Verified facts
What the public records show
CMS Open Payments records show Shery Thomas, MD received $707.38 in general payments during 2025 across 36 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Nurtec Odt, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 269 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $100.79 | 14.2% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $77.96 | 11.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $76.43 | 10.8% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $76.05 | 10.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $68.91 | 9.7% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $42.33 | 6.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.58 | 5.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.77 | 5.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.33 | 5.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.33 | 5.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.87 | 5.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.77 | 3.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.69 | 2.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.33 | 2.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.24 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $707.38 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $77.96 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $76.05 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $68.91 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $61.25 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $49.71 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $42.33 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.77 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.77 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $36.33 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.33 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $35.89 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.87 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 103 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 145 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 147 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
103 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
145 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
97 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
147 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
269 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 542 | 112 |
| Simvastatin | Simvastatin | 441 | 99 |
| Lisinopril | Lisinopril | 414 | 106 |
| Gabapentin | Gabapentin | 406 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 400 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 374 | 110 |
| Furosemide | Furosemide | 367 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 344 | 88 |
| Omeprazole | Omeprazole | 333 | 84 |
| Metoprolol Tartrate | Metoprolol Tartrate | 313 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 306 | 65 |
| Losartan Potassium | Losartan Potassium | 302 | 71 |
| Potassium Chloride | Potassium Chloride | 278 | 64 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 272 | 44 |
| Eliquis | Apixaban | 269 | 42 |
| Alendronate Sodium | Alendronate Sodium | 258 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 220 | 41 |
| Meloxicam | Meloxicam | 209 | 61 |
| Clopidogrel | Clopidogrel Bisulfate | 207 | 52 |
| Buspirone Hcl | Buspirone Hcl | 206 | 44 |
| Sertraline Hcl | Sertraline Hcl | 187 | 53 |
| Carvedilol | Carvedilol | 186 | 39 |
| Mirtazapine | Mirtazapine | 168 | 39 |
| Glimepiride | Glimepiride | 153 | 37 |
| Allopurinol | Allopurinol | 151 | 30 |
| Ozempic | Semaglutide | 147 | 27 |
| Metformin Hcl | Metformin Hcl | 146 | 35 |
| Mounjaro | Tirzepatide | 145 | 27 |
| Montelukast Sodium | Montelukast Sodium | 141 | 35 |
| Alprazolam | Alprazolam | 136 | 33 |
| Lovastatin | Lovastatin | 134 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 131 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 34 |
| Amoxicillin | Amoxicillin | 120 | 89 |
| Prednisone | Prednisone | 120 | 57 |
| Azithromycin | Azithromycin | 107 | 77 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 107 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 105 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 105 | 27 |
| Jardiance | Empagliflozin | 103 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 101 | 24 |
| Januvia | Sitagliptin Phosphate | 99 | 12 |
| Trazodone Hcl | Trazodone Hcl | 98 | 29 |
| Trulicity | Dulaglutide | 97 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 95 | 32 |
| Clonidine Hcl | Clonidine Hcl | 92 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 19 |
| Atenolol | Atenolol | 91 | 18 |
| Xarelto | Rivaroxaban | 91 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 27 |
| Celecoxib | Celecoxib | 89 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 88 | 60 |
| Ondansetron Hcl | Ondansetron Hcl | 85 | 29 |
| Oxycodone Hcl | Oxycodone Hcl | 85 | suppressed |
| Levetiracetam | Levetiracetam | 84 | suppressed |
| Bumetanide | Bumetanide | 82 | 24 |
| Tramadol Hcl | Tramadol Hcl | 81 | 22 |
| Rivastigmine | Rivastigmine Tartrate | 75 | 17 |
| Lorazepam | Lorazepam | 74 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 15 |
| Meclizine Hcl | Meclizine Hcl | 63 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 62 | 22 |
| Ezetimibe | Ezetimibe | 59 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 20 |
| Glipizide | Glipizide | 56 | suppressed |
| Pregabalin | Pregabalin | 55 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | suppressed |
| Clonazepam | Clonazepam | 53 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | 12 |
| Entresto | Sacubitril/Valsartan | 52 | 11 |
| Donepezil Hcl | Donepezil Hcl | 50 | suppressed |
| Famotidine | Famotidine | 50 | 15 |
| Midodrine Hcl | Midodrine Hcl | 50 | 14 |
| Tradjenta | Linagliptin | 49 | 12 |
| Spironolactone | Spironolactone | 46 | 17 |
| Bupropion Xl | Bupropion Hcl | 45 | suppressed |
| Synthroid | Levothyroxine Sodium | 45 | 12 |
| Nystatin | Nystatin | 44 | 18 |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 12 |
| Roflumilast | Roflumilast | 40 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 39 | 34 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Sucralfate | Sucralfate | 39 | suppressed |
| Fluconazole | Fluconazole | 37 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Methocarbamol | Methocarbamol | 34 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | 12 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 21 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 15 |
| Topiramate | Topiramate | 19 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Detrol La | Tolterodine Tartrate | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $707.38 · 36 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, VOQUEZNA, Veozah, XIFAXAN, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error